Which has higher earnings and valuation, STTK or IBIO?

iBio has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shattuck Labs $1M 327.42 -$48.81M -$0.63 N/A iBio $400K 211.14 -$18.38M -$0.58 N/A

Is STTK or IBIO more profitable?

iBio's return on equity of -53.86% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% iBio N/A -53.86% -46.48%

Does the media favor STTK or IBIO?

In the previous week, Shattuck Labs had 10 more articles in the media than iBio. MarketBeat recorded 15 mentions for Shattuck Labs and 5 mentions for iBio. iBio's average media sentiment score of 0.44 beat Shattuck Labs' score of 0.41 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer IBIO or SNDL?

iBio currently has a consensus target price of $5.00, indicating a potential upside of 194.12%. SNDL has a consensus target price of $5.00, indicating a potential upside of 242.47%. Given SNDL's higher probable upside, analysts clearly believe SNDL is more favorable than iBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 SNDL 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, IBIO or SNDL?

SNDL has higher revenue and earnings than iBio. SNDL is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 211.14 -$18.38M -$0.58 N/A SNDL $677.32M 0.55 -$11.29M -$0.03 N/A

Is IBIO or SNDL more profitable?

iBio has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% SNDL -1.19% -1.02% -0.85%

Which has better earnings & valuation, BNTC or IBIO?

iBio has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma $80K 4,641.54 -$37.92M -$1.14 N/A iBio $400K 211.14 -$18.38M -$0.58 N/A

Is BNTC or IBIO more profitable?

Benitec Biopharma's return on equity of -34.82% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% iBio N/A -53.86% -46.48%

Does the media prefer BNTC or IBIO?

In the previous week, iBio had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 5 mentions for iBio and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.67 beat iBio's score of 0.44 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LXEO or IBIO more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% iBio N/A -53.86% -46.48%

Do analysts prefer IBIO or PBYI?

iBio currently has a consensus target price of $5.00, indicating a potential upside of 194.12%. Given iBio's stronger consensus rating and higher possible upside, equities analysts plainly believe iBio is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, IBIO or PBYI?

Puma Biotechnology has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $400K 211.14 -$18.38M -$0.58 N/A Puma Biotechnology $228.40M 1.57 $31.11M $0.48 14.69

Is IBIO or PBYI more profitable?

Puma Biotechnology has a net margin of 10.69% compared to iBio's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Puma Biotechnology 10.69% 20.30% 12.05%

Does the media refer more to IBIO or PBYI?

In the previous week, iBio had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for iBio and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.85 beat iBio's score of 0.44 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iBio (IBIO) Competitors

$1.70 -0.03 (-1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.01 (+0.29%)

As of 06:00 PM Eastern

Compare

IBIO vs. STTK, SNDL, BNTC, LXEO, and PBYI

Should you buy iBio stock or one of its competitors? MarketBeat compares iBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iBio include Shattuck Labs (STTK), SNDL (SNDL), Benitec Biopharma (BNTC), Lexeo Therapeutics (LXEO), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.

How does iBio compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

iBio's return on equity of -53.86% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
iBio	N/A	-53.86%	-46.48%

In the previous week, Shattuck Labs had 10 more articles in the media than iBio. MarketBeat recorded 15 mentions for Shattuck Labs and 5 mentions for iBio. iBio's average media sentiment score of 0.44 beat Shattuck Labs' score of 0.41 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	327.42	-$48.81M	-$0.63	N/A
iBio	$400K	211.14	-$18.38M	-$0.58	N/A

Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, iBio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Shattuck Labs currently has a consensus price target of $11.00, indicating a potential upside of 157.61%. iBio has a consensus price target of $5.00, indicating a potential upside of 194.12%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

iBio beats Shattuck Labs on 10 of the 16 factors compared between the two stocks.

How does iBio compare to SNDL?

iBio (NASDAQ:IBIO) and SNDL (NASDAQ:SNDL) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, iBio had 4 more articles in the media than SNDL. MarketBeat recorded 5 mentions for iBio and 1 mentions for SNDL. SNDL's average media sentiment score of 0.62 beat iBio's score of 0.44 indicating that SNDL is being referred to more favorably in the news media.

Company	Overall Sentiment
iBio	Neutral
SNDL	Positive

iBio has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
SNDL	-1.19%	-1.02%	-0.85%

7.9% of iBio shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SNDL has higher revenue and earnings than iBio. SNDL is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	211.14	-$18.38M	-$0.58	N/A
SNDL	$677.32M	0.55	-$11.29M	-$0.03	N/A

iBio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, SNDL has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

iBio currently has a consensus target price of $5.00, indicating a potential upside of 194.12%. SNDL has a consensus target price of $5.00, indicating a potential upside of 242.47%. Given SNDL's higher probable upside, analysts clearly believe SNDL is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

iBio beats SNDL on 10 of the 17 factors compared between the two stocks.

How does iBio compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Benitec Biopharma has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Benitec Biopharma's return on equity of -34.82% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
iBio	N/A	-53.86%	-46.48%

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

iBio has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,641.54	-$37.92M	-$1.14	N/A
iBio	$400K	211.14	-$18.38M	-$0.58	N/A

In the previous week, iBio had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 5 mentions for iBio and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.67 beat iBio's score of 0.44 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Benitec Biopharma presently has a consensus target price of $27.00, indicating a potential upside of 149.77%. iBio has a consensus target price of $5.00, indicating a potential upside of 194.12%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

iBio beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks.

How does iBio compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

iBio has higher revenue and earnings than Lexeo Therapeutics. iBio is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
iBio	$400K	211.14	-$18.38M	-$0.58	N/A

In the previous week, iBio had 4 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for iBio and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.87 beat iBio's score of 0.44 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
iBio	Neutral

Lexeo Therapeutics' return on equity of -47.48% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
iBio	N/A	-53.86%	-46.48%

Lexeo Therapeutics presently has a consensus target price of $20.14, suggesting a potential upside of 375.07%. iBio has a consensus target price of $5.00, suggesting a potential upside of 194.12%. Given Lexeo Therapeutics' higher possible upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lexeo Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, iBio has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summary

Lexeo Therapeutics beats iBio on 9 of the 15 factors compared between the two stocks.

How does iBio compare to Puma Biotechnology?

iBio (NASDAQ:IBIO) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

7.9% of iBio shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

iBio currently has a consensus target price of $5.00, indicating a potential upside of 194.12%. Given iBio's stronger consensus rating and higher possible upside, equities analysts plainly believe iBio is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	211.14	-$18.38M	-$0.58	N/A
Puma Biotechnology	$228.40M	1.57	$31.11M	$0.48	14.69

In the previous week, iBio had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for iBio and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.85 beat iBio's score of 0.44 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a net margin of 10.69% compared to iBio's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Puma Biotechnology	10.69%	20.30%	12.05%

iBio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Summary

Puma Biotechnology beats iBio on 10 of the 17 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$85.94M	$958.36M	$4.87B	$12.06B
Dividend Yield	N/A	4.84%	9.42%	5.55%
P/E Ratio	-2.93	0.98	18.19	22.06
Price / Sales	211.14	127.56	173.05	105.22
Price / Cash	N/A	20.06	43.40	56.09
Price / Book	1.89	7.90	28.96	6.72
Net Income	-$18.38M	-$4.82M	$118.48M	$337.35M
7 Day Performance	-3.41%	-2.39%	-3.43%	-2.54%
1 Month Performance	-0.58%	3.17%	-0.07%	1.42%
1 Year Performance	N/A	101.07%	11.95%	24.71%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	3.8017 of 5 stars	$1.70 -1.7%	$5.00 +194.1%	N/A	$85.94M	$400K	N/A	100	Analyst Downgrade Gap Up
STTK Shattuck Labs	4.0936 of 5 stars	$4.75 -2.5%	$13.00 +173.7%	+242.1%	$364.23M	$1M	N/A	100	Trending News Analyst Forecast Gap Up
SNDL SNDL	3.4062 of 5 stars	$1.41 -2.1%	$5.00 +254.6%	+9.8%	$362.93M	$677.32M	N/A	2,751
BNTC Benitec Biopharma	1.6066 of 5 stars	$10.40 -1.7%	$27.00 +159.6%	-34.4%	$357.24M	$80K	N/A	20	News Coverage
LXEO Lexeo Therapeutics	2.3442 of 5 stars	$4.50 -0.2%	$20.14 +347.6%	+8.5%	$353.34M	N/A	N/A	58	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. STTK, SNDL, BNTC, LXEO, and PBYI

How does iBio compare to Shattuck Labs?

Summary

How does iBio compare to SNDL?

Summary

How does iBio compare to Benitec Biopharma?

Summary

How does iBio compare to Lexeo Therapeutics?

Summary

How does iBio compare to Puma Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. STTK, SNDL, BNTC, LXEO, and PBYI

How does iBio compare to Shattuck Labs?

Do institutionals & insiders hold more shares of STTK or IBIO?

Is STTK or IBIO more profitable?

Does the media favor STTK or IBIO?

Which has higher earnings and valuation, STTK or IBIO?

Which has more risk & volatility, STTK or IBIO?

Do analysts rate STTK or IBIO?

Summary

How does iBio compare to SNDL?

Does the media refer more to IBIO or SNDL?

Is IBIO or SNDL more profitable?

Do insiders & institutionals believe in IBIO or SNDL?

Which has stronger valuation & earnings, IBIO or SNDL?

Which has more volatility and risk, IBIO or SNDL?

Do analysts prefer IBIO or SNDL?

Summary

How does iBio compare to Benitec Biopharma?

Which has more risk and volatility, BNTC or IBIO?

Is BNTC or IBIO more profitable?

Do insiders and institutionals believe in BNTC or IBIO?

Which has better earnings & valuation, BNTC or IBIO?

Does the media prefer BNTC or IBIO?

Do analysts recommend BNTC or IBIO?

Summary

How does iBio compare to Lexeo Therapeutics?

Which has higher earnings & valuation, LXEO or IBIO?

Does the media prefer LXEO or IBIO?

Is LXEO or IBIO more profitable?

Do analysts prefer LXEO or IBIO?

Do institutionals & insiders have more ownership in LXEO or IBIO?

Which has more risk and volatility, LXEO or IBIO?

Summary

How does iBio compare to Puma Biotechnology?

Do insiders and institutionals hold more shares of IBIO or PBYI?

Do analysts prefer IBIO or PBYI?

Which has higher valuation and earnings, IBIO or PBYI?

Does the media refer more to IBIO or PBYI?

Is IBIO or PBYI more profitable?

Which has more risk & volatility, IBIO or PBYI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools